Can Hormone Therapy Restore Sexual Function After Menopause?
Not on the scale the earlier version of this article claimed. This is a systematic review and meta-analysis update, not a single trial: 47 randomized controlled trials with 35,912 participants were included in the review, and 34 trials with 15,079 participants were pooled in the meta-analysis. The pooled result was that estrogen therapy, estrogen plus progestogen therapy, tibolone, and selective estrogen receptor modulators, compared with control, may result in no effect to small benefit on a composite sexual function score. The authors’ summary is that hormone therapy may slightly improve sexual functioning.
Dr. Kumar’s Take
Sexual health is a real component of well-being that gets skipped in menopause visits, and this review is worth reading for what it does and does not show. The pooled effects are small, and for estrogen plus progestogen the confidence interval crosses zero, so I would not present hormone therapy to a patient as a reliable fix for low desire. What I take from it is narrower and still useful: if a woman is already considering hormone therapy for other menopausal symptoms, a possible small improvement in sexual function belongs in that conversation rather than being offered as the reason to start.
Study Snapshot
This update searched 13 databases and clinical trial registries, including CENTRAL, Embase, MEDLINE, PsycINFO, Web of Science, CINAHL, LILACS, DARE, ClinicalTrials.gov, the International Clinical Trials Registry Platform, the Iranian Registry of Clinical Trials, the Chinese Clinical Trial Registry, and ISRCTN, from December 2012 to March 30, 2022, with backward reference searching on all retrieved full texts. It builds on the 2013 Cochrane review of hormone therapy and sexual function, and the pooled analyses combine newly identified studies with those already included in that review. Study quality was assessed with the Cochrane RoB.2 tool, and data were pooled in random-effects meta-analyses. Forty-seven randomized controlled trials with 35,912 participants entered the systematic review; 34 trials with 15,079 participants entered the meta-analysis.
Results in Real Numbers
- Estrogen therapy: standardized mean difference 0.16 (95% CI, 0.02 to 0.29), I² = 59%, 2,925 participants across 16 studies
- Estrogen plus progestogen therapy: standardized mean difference 0.11 (95% CI, -0.07 to 0.29), I² = 65%, 2,432 participants across 7 studies
- Tibolone: standardized mean difference 0.15 (95% CI, 0.02 to 0.28), I² = 0%, 916 participants across 2 studies
- Selective estrogen receptor modulators: standardized mean difference 0.18 (95% CI, 0.06 to 0.30), I² = 0%, 1,058 participants across 4 studies
- Interpretation the authors give these numbers: no effect to small benefit on the sexual function composite score
- Heterogeneity across studies: low to high
Who Benefits Most
The participants were perimenopausal and postmenopausal women, and the pooled outcome reported was a composite sexual function score. Across the four treatment classes the effect estimates sit close together, between 0.11 and 0.18, and only the estrogen plus progestogen estimate has a confidence interval that includes zero. Context from the review’s background is relevant to who might be considered: hormone therapy is first-line treatment for moderate to severe genitourinary symptoms of menopause, the genitourinary syndrome of menopause affects half of postmenopausal women and causes lack of lubrication, discomfort, and pain during sexual activity, and postmenopausal sexually active women with female sexual dysfunction are nearly four times more likely to have genitourinary syndrome of menopause than those without it. Decreasing genitourinary symptoms, and decreasing sleep disturbance, are the proposed routes by which hormone therapy might improve sexual function.
Safety, Limits, and Caveats
The effect sizes here are small, and a standardized mean difference of roughly 0.1 to 0.2 on a composite score is not the same thing as a woman noticing a change in her sex life. Heterogeneity ranged from low to high, reaching I² = 59% for estrogen therapy and 65% for estrogen plus progestogen, so the trials pooled were not measuring the same thing in the same way. The estrogen plus progestogen estimate is compatible with no benefit at all. Sexual function is also not a purely hormonal outcome: the International Menopause Society recommends a biopsychosocial approach that accounts for health status, neurochemical balance, psychological issues, interpersonal concerns, and sociocultural beliefs and values.
Practical Takeaways
- Treat a possible small improvement in sexual function as one consideration among several when discussing hormone therapy for other menopausal symptoms, not as a standalone indication
- Hormone therapy remains first-line treatment for moderate to severe genitourinary symptoms of menopause
- Ask about genitourinary symptoms directly, since the syndrome affects half of postmenopausal women and produces lack of lubrication, discomfort, and pain during sexual activity
- Distressing sexual problems peak in midlife, while sexual problems without distress tend to increase with age, so ask about distress and not just about symptoms
- Expect a biopsychosocial workup, because psychological, interpersonal, and sociocultural factors sit alongside the hormonal ones
- Seek providers comfortable discussing sexual health
What This Means for Perimenopause and Menopause Care
Sexual well-being belongs in menopause consultations, and 71% to 76% of middle-aged women say sexual activity is an important aspect of their lives. What this update supports is a modest, honest claim: hormone therapy may slightly improve sexual functioning, and that potential small benefit should be weighed when treatment options for other menopausal symptoms are on the table. I would rather patients hear that framing than a promise the evidence cannot carry.
Related Studies and Research
- Genitourinary Syndrome of Menopause: A Narrative Review
- Recurrent Urinary Tract Infection in Older Outpatient Women
- Effects of menopause on temperature regulation
- Sleep disturbance associated with the menopause
- Episode 27: Perimenopause, Menopause, and HRT - What Every Woman Should Know
FAQs
How large is the benefit of hormone therapy on sexual function?
Small at best. The pooled standardized mean differences ranged from 0.11 for estrogen plus progestogen therapy to 0.18 for selective estrogen receptor modulators, which the authors describe as no effect to small benefit on the sexual function composite score.
Does one type of hormone therapy clearly beat the others?
The estimates for estrogen therapy, tibolone, and selective estrogen receptor modulators were similar and their confidence intervals excluded zero, while the estrogen plus progestogen estimate of 0.11 had a confidence interval from -0.07 to 0.29, which includes no effect.
Why might hormone therapy affect sexual function at all?
The proposed routes are indirect: decreasing the genitourinary symptoms of menopause, which cause lack of lubrication, discomfort, and pain during sexual activity, and decreasing sleep disturbance.
Bottom Line
Pooling 34 randomized trials with 15,079 participants, this update found that hormone therapy may slightly improve sexual functioning, with small effects and heterogeneity ranging from low to high. That potential small benefit is worth raising when discussing treatment options for other menopausal symptoms, and it is not a reason on its own to start therapy.
